Superstring Capital Management has reduced its stake in UroGen Pharma Ltd. (URGN), selling 330,983 shares for approximately $6.64 million in the first quarter, according to an SEC filing dated May 14, 2026. This transaction reflects a decrease in the value of UroGen’s position by $9.86 million due to both the sale and share price fluctuations. Despite the reduction, UroGen still constitutes 5% of Superstring’s reported assets, indicating it remains a significant holding.

UroGen has experienced a remarkable 600% increase in share price over the past year, significantly outperforming the S&P 500’s 28% rise. This surge comes as the company continues to achieve clinical and commercial milestones, including promising results for its bladder cancer therapies. The recent approval of ZUSDURI and positive Phase 3 data for UGN-103 bolster UroGen’s prospects, suggesting a potential shift toward a more robust oncology platform.

For investors, this sale may signal profit-taking rather than a loss of confidence, as UroGen’s ongoing clinical advancements position it well for future growth. The key takeaway is that UroGen’s strong pipeline and market performance could make it an attractive long-term investment, especially as it seeks to establish a durable oncology franchise.

Source: fool.com